| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3ccb9e28f76f3f135717d1e723a452bb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate |
2019-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74514eea611818b3b3b4cf9c16957039
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df160c4cb49154e5ae075413af894f69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_943bc305d1368a885fe3e700ccf620da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82bafe29bb5a948bee2face7dc1490b6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9222cd865edd46e7cf30194636c8f571
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b748cf2347792487a46b54515789ed3c |
| publicationDate |
2020-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-110835650-A |
| titleOfInvention |
Biomarkers for Breast Cancer Metastasis and Prognostic Diagnosis |
| abstract |
The present invention relates to a biomarker for breast cancer metastasis and prognosis diagnosis. The biomarker is meR342-EZH2. The inventor found and confirmed that meR342-EZH2 can promote the EMT process of breast cancer and breast cancer cells through a series of experiments. In vitro invasion and metastasis and in vivo distant metastasis, through the correlation analysis of case grading, metastasis and prognosis of breast cancer patients, it was found that meR342‑EZH2 high expression and breast cancer patients had larger tumors, higher grades and more distant metastasis The foci were positively correlated, and high expression of meR342‑EZH2 predicted a lower five-year survival rate in breast cancer patients. Therefore, meR342-EZH2 can be used to prepare or screen breast cancer metastasis diagnostic reagents and breast cancer prognosis diagnostic reagents, providing a new diagnosis and evaluation method for breast cancer metastasis and prognosis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111378754-A |
| priorityDate |
2019-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |